This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the
safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy
(ULT) for up to six months. Allopurinol will be dosed according to the local product label,
at the discretion of the Investigator, to achieve an optimal, medically appropriate dose for
each patient.